** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6.3% to A$14.100, their highest levels since February 7
** Stock on track for its second consecutive session of gains, if trend holds
** The drug manufacturer gets rare paediatric disease designation from the U.S. Food and Drug Administration (FDA)
** Designation for NNZ-2591 in each of Pitt Hopkins syndrome and Angelman syndrome - Neuren
** NNZ-2591 used for treatment of any traumatic brain injury
** Stock has risen 11.6% so far this year, as of 0054 GMT
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。